At 11.6% CAGR, the North America Glucose Monitoring Devices Market is Projected to be Worth US$ 14,409.58 million by 2030, Says Business Market Insights

According to Business Market Insights research, the North America glucose monitoring devices market was valued at US$ 5,987.78 million in 2022 and is expected to reach US$ 14,409.58 million by 2030, registering a CAGR of 11.6% from 2022 to 2030. Rising incidence of diabetes is a critical factor attributed to the North America glucose monitoring devices market expansion.

Diabetes is a life-threatening chronic disease with no specialized cure. It is mainly caused by the body’s inability to produce or effectively utilize the hormone insulin. This inability prevents the body from adequately regulating blood glucose levels. There are two types of diabetes—diabetes type-I (also known as diabetes insipidus) and diabetes type-II (also termed diabetes mellitus). The incidence and prevalence of diabetes are steadily increasing across the world. Type 2 diabetes is the most prevalent form of diabetes and has increased alongside cultural and societal changes. In high-income countries, up to 91% of adults with the disease have type 2 diabetes. According to International Diabetes Federation (IDF), approximately 537 million people were living with diabetes in 2022 and is expected to reach 738 million by 2045 globally. Patients suffering from diabetes require frequent monitoring and external administration of insulin. The rising prevalence of diabetes across the globe is driving the growth of the North America glucose monitoring devices market.

On the contrary, high cost of glucose monitoring devices hampers the North America glucose monitoring devices market.  

Based on type, the North America glucose monitoring devices market is bifurcated into continuous glucose monitoring devices and self-glucose monitoring devices. The self-glucose monitoring devices held 59.5% share of North America glucose monitoring devices market in 2022, amassing US$ 3,561.70 million. It is projected to garner US$ 8,387.68 million by 2030 to expand at 11.3% CAGR during 2022–2030. 

Based on application, the North America glucose monitoring devices market is bifurcated into type 1 diabetes and type 2 diabetes. The type 2 diabetes segment held 69.6% share of North America glucose monitoring devices market in 2022, amassing US$ 4,170.21 million. It is projected to garner US$ 9,949.40 million by 2030 to expand at 11.5% CAGR during 2022–2030.

Based on testing site, the North America glucose monitoring devices market is bifurcated into fingertip testing and alternate site testing. The fingertip testing segment held 70.2% share of North America glucose monitoring devices market in 2022, amassing US$ 4,205.77 million. It is projected to garner US$ 10,403.89 million by 2030 to expand at 12.0% CAGR during 2022–2030.

Based on end user, the North America glucose monitoring devices market is bifurcated into healthcare setting and self/homecare. The self/homecare segment held 66.8% share of North America glucose monitoring devices market in 2022, amassing US$ 3,997.99 million. It is projected to garner US$ 9,335.15 million by 2030 to expand at 11.2% CAGR during 2022–2030.

 Based on country, the North America glucose monitoring devices market has been categorized into the US, Canada, and Mexico. Our regional analysis states that the US captured 82.7% share of North America glucose monitoring devices market in 2022. It was assessed at US$ 4,951.02 million in 2022 and is likely to hit US$ 12,135.85 million by 2030, exhibiting a CAGR of 11.9% during 2022–2030.      

Key players operating the North America glucose monitoring devices market are B. Braun SE, F. Hoffmann-La Roche Ltd, LifeScan Inc, Medtronic Plc, Abbott Laboratories, Ypsomed Holding AG, Senseonics Holdings Inc, Nipro Corp, GE HealthCare Technologies Inc, and Terumo Corp, among others.

• In June-2022, Roche's Accu-Chek Inform II hospital blood glucose system was approved by Health Canada for intensive care use. The Accu-Chek Inform II solution has brought and continues to bring high-end laboratory standards to bedside glucose testing and helps ensure the safety of patients.
• In Oct-2022, Life Scan launched OneTouch Solutions, an eCommerce site offering a comprehensive and convenient choice of personalized wellness programs to help people manage diabetes. OneTouch Solutions is available to US consumers and offered to healthcare providers, payors, and employers as a reimbursed adjudicated option.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com